Abeona Therapeutics Net Income
| ABEO Stock | USD 5.27 0.10 1.93% |
As of the 4th of February, Abeona Therapeutics shows the risk adjusted performance of 0.0374, and Mean Deviation of 2.92. Abeona Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Abeona Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 233.4149 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -57.4 M | -54.5 M | |
| Net Loss | -57.4 M | -60.2 M | |
| Net Loss | -39.1 M | -41.1 M | |
| Net Loss | (1.40) | (1.47) | |
| Net Income Per E B T | 0.91 | 0.81 |
Abeona | Net Income | Build AI portfolio with Abeona Stock |
Evaluating Abeona Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Abeona Therapeutics's fundamental strength.
Latest Abeona Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Abeona Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Abeona Therapeutics financial statement analysis. It represents the amount of money remaining after all of Abeona Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Abeona Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Abeona Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (63.73 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Abeona Net Income Regression Statistics
| Arithmetic Mean | (39,433,186) | |
| Coefficient Of Variation | (75.09) | |
| Mean Deviation | 25,493,587 | |
| Median | (39,696,000) | |
| Standard Deviation | 29,611,358 | |
| Sample Variance | 876.8T | |
| Range | 89.4M | |
| R-Value | (0.78) | |
| Mean Square Error | 363T | |
| R-Squared | 0.61 | |
| Significance | 0.0002 | |
| Slope | (4,586,894) | |
| Total Sum of Squares | 14029.3T |
Abeona Net Income History
Other Fundumenentals of Abeona Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Abeona Therapeutics Net Income component correlations
Abeona Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Abeona Therapeutics is extremely important. It helps to project a fair market value of Abeona Stock properly, considering its historical fundamentals such as Net Income. Since Abeona Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Abeona Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Abeona Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Abeona diversify its offerings? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Abeona Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 1.21 | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Investors evaluate Abeona Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Abeona Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Abeona Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Abeona Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Abeona Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Abeona Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Abeona Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Abeona Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Abeona Therapeutics.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Abeona Therapeutics on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Abeona Therapeutics or generate 0.0% return on investment in Abeona Therapeutics over 90 days. Abeona Therapeutics is related to or competes with Tenaya Therapeutics, Eledon Pharmaceuticals, Puma Biotechnology, Humacyte, Voyager Therapeutics, Arcturus Therapeutics, and Foghorn Therapeutics. Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threaten... More
Abeona Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Abeona Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Abeona Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.77 | |||
| Information Ratio | 0.0267 | |||
| Maximum Drawdown | 26.76 | |||
| Value At Risk | (5.48) | |||
| Potential Upside | 6.16 |
Abeona Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Abeona Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Abeona Therapeutics' standard deviation. In reality, there are many statistical measures that can use Abeona Therapeutics historical prices to predict the future Abeona Therapeutics' volatility.| Risk Adjusted Performance | 0.0374 | |||
| Jensen Alpha | 0.0674 | |||
| Total Risk Alpha | (0.09) | |||
| Sortino Ratio | 0.0288 | |||
| Treynor Ratio | 0.0775 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Abeona Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Abeona Therapeutics February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0374 | |||
| Market Risk Adjusted Performance | 0.0875 | |||
| Mean Deviation | 2.92 | |||
| Semi Deviation | 3.56 | |||
| Downside Deviation | 3.77 | |||
| Coefficient Of Variation | 2513.65 | |||
| Standard Deviation | 4.06 | |||
| Variance | 16.49 | |||
| Information Ratio | 0.0267 | |||
| Jensen Alpha | 0.0674 | |||
| Total Risk Alpha | (0.09) | |||
| Sortino Ratio | 0.0288 | |||
| Treynor Ratio | 0.0775 | |||
| Maximum Drawdown | 26.76 | |||
| Value At Risk | (5.48) | |||
| Potential Upside | 6.16 | |||
| Downside Variance | 14.21 | |||
| Semi Variance | 12.66 | |||
| Expected Short fall | (3.00) | |||
| Skewness | 1.27 | |||
| Kurtosis | 5.16 |
Abeona Therapeutics Backtested Returns
Abeona Therapeutics appears to be moderately volatile, given 3 months investment horizon. Abeona Therapeutics secures Sharpe Ratio (or Efficiency) of 0.11, which signifies that the company had a 0.11 % return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for Abeona Therapeutics, which you can use to evaluate the volatility of the firm. Please makes use of Abeona Therapeutics' risk adjusted performance of 0.0374, and Mean Deviation of 2.92 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Abeona Therapeutics holds a performance score of 9. The firm shows a Beta (market volatility) of 1.96, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Abeona Therapeutics will likely underperform. Please check Abeona Therapeutics' potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to make a quick decision on whether Abeona Therapeutics' price patterns will revert.
Auto-correlation | -0.59 |
Good reverse predictability
Abeona Therapeutics has good reverse predictability. Overlapping area represents the amount of predictability between Abeona Therapeutics time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Abeona Therapeutics price movement. The serial correlation of -0.59 indicates that roughly 59.0% of current Abeona Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.59 | |
| Spearman Rank Test | -0.3 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Abeona Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Abeona Therapeutics reported net income of (63.73 Million). This is 118.67% lower than that of the Biotechnology sector and 190.99% lower than that of the Health Care industry. The net income for all United States stocks is 111.16% higher than that of the company.
Abeona Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Abeona Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Abeona Therapeutics could also be used in its relative valuation, which is a method of valuing Abeona Therapeutics by comparing valuation metrics of similar companies.Abeona Therapeutics is currently under evaluation in net income category among its peers.
Abeona Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Abeona Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Abeona Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Abeona Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Abeona Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Abeona Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Abeona Therapeutics' value.| Shares | Silverarc Capital Management, Llc | 2025-06-30 | 917.9 K | Jpmorgan Chase & Co | 2025-06-30 | 831.1 K | 683 Capital Management Llc | 2025-06-30 | 750 K | Kennedy Capital Management Inc | 2025-06-30 | 672 K | State Street Corp | 2025-06-30 | 585.9 K | Nan Fung Trinity (hk) Ltd | 2025-06-30 | 560.8 K | Simplify Asset Management Inc. | 2025-06-30 | 558.6 K | Citigroup Inc | 2025-06-30 | 548.1 K | Newtyn Management Llc | 2025-06-30 | 480 K | Nantahala Capital Management, Llc | 2025-06-30 | 4.4 M | Adage Capital Partners Gp Llc | 2025-06-30 | 3.1 M |
Abeona Fundamentals
| Return On Equity | 0.76 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | 205.88 % | ||||
| Operating Margin | (208.02) % | ||||
| Current Valuation | 93.37 M | ||||
| Shares Outstanding | 54.19 M | ||||
| Shares Owned By Insiders | 10.97 % | ||||
| Shares Owned By Institutions | 68.50 % | ||||
| Number Of Shares Shorted | 13.82 M | ||||
| Price To Earning | 0.11 X | ||||
| Price To Book | 1.61 X | ||||
| Price To Sales | 700.42 X | ||||
| Gross Profit | (29.28 M) | ||||
| EBITDA | (56.62 M) | ||||
| Net Income | (63.73 M) | ||||
| Cash And Equivalents | 20.1 M | ||||
| Cash Per Share | 3.38 X | ||||
| Total Debt | 23.05 M | ||||
| Debt To Equity | 0.42 % | ||||
| Current Ratio | 2.21 X | ||||
| Book Value Per Share | 3.27 X | ||||
| Cash Flow From Operations | (56.02 M) | ||||
| Short Ratio | 12.56 X | ||||
| Earnings Per Share | 1.21 X | ||||
| Target Price | 20.64 | ||||
| Number Of Employees | 136 | ||||
| Beta | 1.13 | ||||
| Market Capitalization | 280.17 M | ||||
| Total Asset | 108.93 M | ||||
| Retained Earnings | (813.26 M) | ||||
| Working Capital | 84.27 M | ||||
| Current Asset | 31.95 M | ||||
| Current Liabilities | 6.51 M | ||||
| Net Asset | 108.93 M |
About Abeona Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Abeona Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abeona Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abeona Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Abeona Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abeona Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abeona Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Abeona Stock
Moving against Abeona Stock
| 0.65 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.52 | EVGN | Evogene | PairCorr |
| 0.5 | GNLX | Genelux Common | PairCorr |
| 0.48 | EDIT | Editas Medicine | PairCorr |
| 0.48 | ABP | Abpro Holdings | PairCorr |
The ability to find closely correlated positions to Abeona Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abeona Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abeona Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abeona Therapeutics to buy it.
The correlation of Abeona Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abeona Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abeona Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abeona Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Will Biotechnology sector continue expanding? Could Abeona diversify its offerings? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Abeona Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 1.21 | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Investors evaluate Abeona Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Abeona Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Abeona Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Abeona Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Abeona Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Abeona Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.